Weekly Recap: CAR NK safety and efficacy and Dose escalation to 4B cells
Nkarta, Inc. (NASDAQ:NKTX) said streamlined CAR NK cell trials raising doses from 1B to 4B cells show strong safety and promising efficacy, prompting plans for pivotal studies by 2027 while durability and retreatment signals are monitored and data will be presented at ACR 2026.Previous Week RecapTh…